Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia

NCT05705492 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT05705492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
July 17, 2024
Completion date
June 30, 2027
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma, advanced esophageal carcinoma, advanced lung carcinoma, advanced malignant solid neoplasm, locally advanced colorectal carcinoma, locally advanced esophageal carcinoma, locally advanced gastric carcinoma, locally advanced hepatocellular carcinoma, metastatic colorectal carcinoma (mcrc), metastatic esophageal carcinoma